Everything You Need to Know About the GLP-1 Pill

The Food and Drug Administration (FDA) has approved oral formulations of Wegovy and Rybelsus. The active ingredient in both drugs is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonistalso used in Ozempic.

Experts describe the development of oral GLP-1 medication as a “pivotal” improvement in the accessibility and adherence to obesity drugs.

As of February 2026, only Wegovy and Rybelsus are available in pill form.

Read on to learn more about the new FDA-approved weight loss pills, how they work, and where they are available.

The GLP-1 pill is an alternative to injectable GLP-1 medication. There are currently three FDA-approved options: one Wegovy pill and two Rybelsus pills. One of the Ryblesus pills is due to be renamed the Ozempic Pill.

The Wegovy pill is for weight loss. The Rybelsus pills are for blood sugar regulation in people with type 2 diabetes and are available in two formulations, R1 and R2. In early February 2026, Novo Nordisk decided to rename the R2 formulation to the Ozempic Pill, which will be available in the second quarter of the year.

Each pill comes in different doses, shown below. They also differ in their inactive ingredients and are not interchangeable drugs.

GLP-1 pills slow digestion, reduce appetite and food cravings, lower blood sugar, and may promote weight loss. They have the same effects on the body as GLP-1 injections because they contain the same active ingredient. However, how the pills work in the body differs slightly.

Novo Nordisk, the manufacturer of the Wegovy pill, explains that one of the main barriers to creating an effective GLP-1 pill was finding a way for the drug to survive the digestive process.

Typically, oral semaglutide is poorly absorbed because it is a protein-like molecule that the stomach naturally breaks down. Research shows that oral semaglutide typically has a bioavailability of just 0.4% to 1%.

The Wegovy and Rybelsus pills use an absorption enhancer called sodium N-(8-[2-hydroxybenzoyl]amino) caprylate (SNAC), which protects the drug from stomach acid and enzymes, allowing it to survive long enough to be absorbed through the stomach lining and into the bloodstream.

Both oral and injectable semaglutide remain in the bloodstream for around 5 weeks after a person’s last dose. Knowing this can help with planning for surgery, pregnancy, or starting new medications.

GLP-1 pills are for adults aiming to lose weight or to improve their blood sugar regulation and management.

The Wegovy pill is for adults with obesity or overweight and weight-related health conditions. It is approved for:

People must combine the Wegovy pill with a reduced-calorie diet and increased exercise for it to be effective for weight loss.

To get a prescription for the Rybelsus pill, a person must have type 2 diabetes or have type 2 diabetes and be at risk of certain heart conditions or stroke. Doctors may also prescribe Rybelsus off-label for weight loss.

“Patients with needle phobia, a preference for pill-based routines, or good adherence to oral administration guidelines may be better suited to oral GLP-1 formulations like semaglutide (Rybelsus, Wegovy), which can enhance treatment acceptance and potentially offer strong glycemic or weight control.

In contrast, injectable GLP-1s such as Ozempic or Wegovy are often preferred for those seeking superior weight loss efficacy, weekly dosing convenience, or who have gastrointestinal absorption issues, as they provide higher bioavailability and consistent metabolic benefits.

The choice is guided by factors like patient preferences, adherence potential, side effect tolerability, comorbidities, administration logistics, and cost-access considerations, emphasizing shared decision-making for optimal outcomes.”

_{Quotes represent the opinions of our medical experts. All content is strictly informational and should not be considered medical advice.}

People should take Wegovy tablets by mouth once a day. They should take them with up to 4 ounces of water and on an empty stomach. People should not take this medication with drinks other than water.

A person must also wait 30 minutes before eating food or drinking anything other than water. They should also wait 30 minutes before taking other medication after Wegovy.

According to the prescribing information, the recommended dosage regimen for the Wegovy pill is as follows.

If a person wants to switch from the Wegovy injection to the Wegovy pill, they can switch from 2.4 mg injection to the 25 mg tablets with a 1-week break in between their last injection and their first oral Wegovy dose.

A person should always consult a doctor before starting or switching to a GLP-1.

GLP-1 pills are typically as effective as injectables because they contain the same active ingredient.

A 71-week 2025 study funded by Novo Nordisk looked into whether oral semaglutide helped adults without diabetes lose weight. Participants received either a 25 mg once-daily dose of oral semaglutide or a placebo. They also received guidance on diet and exercise.

The mean weight loss was much greater in the oral semaglutide group compared with the placebo group. The mean weight loss in the semaglutide group was 13.6%, compared with 2.2% in the placebo group.

Participants taking semaglutide reported gastrointestinal side effects, such as nausea, more often than those taking a placebo.

In another study funded by Novo Nordisk, participants with obesity and overweight but without diabetes took 50 mg of oral semaglutide.

The participants taking semaglutide had a mean weight loss of 15.1% compared to 2.4% in the placebo group. Again, side effects were more common in the semaglutide group compared to the placebo group.

Both trials show that oral semaglutide is very effective for weight loss when used in conjunction with a reduced-calorie diet and exercise.

A 2019 study showed that in adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone, oral semaglutide significantly reduced blood sugar compared to placebo.

It study also found that weight loss from oral semaglutide in the study participants was dose-dependent. Higher doses tended to result in more weight loss compared to placebo.

GLP-1 medications can cause side effects. People taking the GLP-1 pill may experience some of the most commonly reported side effects, such as:

It notes that people will react differently to taking Wegovy and advises people to work with a healthcare professional to help them manage any side effects they experience.

The price people pay for GLP-1 pills will depend on their health insurance and whether they are eligible for any savings programs. It is important to check the terms and conditions of any savings scheme or payment plan, as Novo Nordisk can change or cancel programs at any time.

*Most people will not pay the list price for medication. This price is the price the manufacturer sets for a wholesaler before any discounts are applied.

**The self-pay price may change depending on the dose a person chooses. Prices will rise to $199 a month for certain doses after April 15, 2026.

People can save on Wegovy and Rybelsus pills with Novo Nordisk’s Savings Card. This card is for people with commercial health insurance and can reduce the cost of medication to $25 a month. The maximum savings the card offers are $100 for a 1-month supply, $200 for a 2-month supply, and $300 for a 3-month supply. More information about eligibility criteria is available on the Wegovy and Rybelsus websites.

Several reputable telehealth pharmacies offer GLP-1 as a pill alongside the injectable version of the drug.

To date, there is only one study directly comparing the semaglutide injection with the semaglutide pill. The authors noted that existing data come from separate trials of each form of semaglutide.

This retrospective observational study, which examined patient data from clinical practice, included 105 adults with type 2 diabetes and ran from 2019 to 2022. According to this study, both forms of semaglutide appear to be effective for lowering blood sugar and helping with weight loss in people with type 2 diabetes.

The study showed that the GLP-1 injection led to slightly higher weight loss compared to the pill. Those taking the GLP-1 injection lost 5.26 kilograms (kg) of weight loss versus 3.64 kg in the GLP-1 pill group. However, the authors stated this is not a clinically significant difference.

The GLP-1 pill tended toward slightly better blood sugar reduction. Again, the authors concluded this did not show a significant advantage over the GLP-1 injection.

Side effects were more common in the oral semaglutide group (16.7%) than in the injection group (4.9%).

Below, we lay out some comparisons between the GLP-1 injection and the pill.

Yes, the GLP-1 drug semaglutide is available as a once-daily pill. It is only available on prescription, and people must meet eligibility criteria concerning their BMI and weight-related health conditions.

Yes, the GLP-1 drug semaglutide is available as a once-daily pill. It is only available on prescription, and people must meet eligibility criteria concerning their BMI and weight-related health conditions.

A 2025 study comparing the GLP-1 pill with the GLP-1 injection found their effectiveness for lowering blood sugar and aiding weight loss in adults with type 2 diabetes were comparable.

The GLP-1 injection was slightly better for weight loss compared to the pill. The pill also caused more side effects than the injection.

However, the authors of this study noted that there were no clinically significant differences, and both drugs were effective for their intended uses.

A 2025 study comparing the GLP-1 pill with the GLP-1 injection found their effectiveness for lowering blood sugar and aiding weight loss in adults with type 2 diabetes were comparable.

The GLP-1 injection was slightly better for weight loss compared to the pill. The pill also caused more side effects than the injection.

However, the authors of this study noted that there were no clinically significant differences, and both drugs were effective for their intended uses.

Yes, you can lose weight with the GLP-1 pill. Trials funded by Novo Nordisk have shown a mean weight loss of up to 15% from oral semaglutide in adults without diabetes.

Yes, you can lose weight with the GLP-1 pill. Trials funded by Novo Nordisk have shown a mean weight loss of up to 15% from oral semaglutide in adults without diabetes.

The GLP-1 pill contains the same active ingredient as Ozempic, semaglutide. However, GLP-1 pills are only available under the brand names Wegovy and Rybelsus, alongside their generic counterpart, semaglutide.

The GLP-1 pill contains the same active ingredient as Ozempic, semaglutide. However, GLP-1 pills are only available under the brand names Wegovy and Rybelsus, alongside their generic counterpart, semaglutide.

The Danish pharmaceutical company Novo Nordisk makes Wegovy. It is currently available as an injection and an oral pill.

The Danish pharmaceutical company Novo Nordisk makes Wegovy. It is currently available as an injection and an oral pill.

Wegovy and Rybelsus are now available in pill form. Oral GLP-1 drugs may make taking GLP-1 drugs easier as they do not require people to self-inject medication.

However, oral GLP-1s can cause more noticeable digestive side effects, and some research shows that the injectable version may be slightly more effective for weight loss.

Work with a doctor to discuss whether GLP-1 medication is appropriate for your health goals.